vendredi 8 mars 2019

Onco Actu du 8 mars 2019


1. BIOLOGIE



Study in mice suggests why cancer commonly spreads to the liver [Cancer Research UK]











1.1 BIOLOGIE - GÈNES



Mutagenic Processes in Cancer Cell Lines Can Be Persistent, Episodic [Genome Web]











Major mutation pattern in cancer occurs in bursts [Wellcome Sanger Institute]










1.4 BIOLOGIE - TECHNOS



NCI Develops High-Throughput, Low-Cost Sequencing Assay for HPV Research [Genome Web]











2.11 ETIOLOGIE - ALIMENTATION



Research Check: do we need to worry about glyphosate in our beer and wine? [The Conversation]










2.6 ETIOLOGIE - ENVIRONNEMENT



EU food agency must release glyphosate studies: court [Reuters]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



New optical imaging system could be deployed to find tiny tumors [MIT]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



FDA Grants Breakthrough Designation to Paige.AI [Paige]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Combinatorial Signature Outperforms Standard-of-care Methods in Stratifying Colorectal Cancer Patients for Prognosis [AACR]











5.10 TRAITEMENTS - ESSAIS



Making Cancer Clinical Trials Available to More Patients [NCI]










Clinical trial costs go under the microscope [Nature Medicine]










5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Anatomy of a deal: How Merck closed Immune Design for $300M [Fierce Biotech]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio [Cellectis]











5.12.6 IMMUNOTHÉRAPIES - AMM



European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer [Roche]










Roche gets European approval for Tecentriq combo vs. lung cancer [Reuters]











5.2 PHARMA



Bayer submits European marketing authorization application for darolutamide [Bayer]











AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients [AbbVie]











Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions [Roche]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Oncternal grows by merger again, this time swallowing GTx [Fierce Biotech]











5.4 TRAITEMENTS - ECONOMIE



A quantum of innovation and the incentives to match [STAT]











Leukaemia drug gets initial ‘no’ for NHS in England [Cancer Research UK]











Dutch join backlash at expensive drugs by making their own [Reuters]











6. LUTTE CONTRE LES CANCERS



Banking on health [Nature Biotechnology]










6.10 POLITIQUES



UK considers post-Brexit research fund open to world [Nature]











6.10.1 POLITIQUES (USA)



No Letup Seen in Crackdown on Youth Vaping by FDA After Gottlieb [Bloomberg]











6.11 PATIENTS



For Alex Trebek, the Toughest Question: Can He Face Down Pancreatic Cancer? [NY Times]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



The sad story of cancer patient Gemma Nuttall, Hallwang Clinic, and crowdfunding [Respectful Insolence]











6.8 COMMUNICATION



The $100,000 dark-money mystery group behind a pharma-bashing Facebook campaign [STAT]